Author: Mary Ann Caputo

Dan Zandberg, MD Introduction Currently, two immunotherapy medications, Nivolumab (Opdivo) and Pembrolizumab (Keytruda) are approved in the USA for recurrent and or metastatic squamous cell carcinoma of head and neck (HNSCC) after a patient received and failed “platinum” based chemotherapy. Both Nivolumab...

Robert L. Ferris, MD, PhD Clinical trials are a key research tool for advancing medical knowledge and patient care. Clinical research is done only if doctors do not know whether a new approach works well in people and is safe and...

Join Our E-Mail List

Join our mailing list!

Receive a free welcome packet and learn more about SPOHNC.